-Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

Press/Media

Period3 Oct 2023

Media coverage

2

Media coverage

  • Title-Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
    Media name/outletM2 PressWIRE
    Country/TerritoryUnited States
    Date3/10/23
    PersonsLeon Kircik
  • Title-Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date3/10/23
    PersonsLeon Kircik